Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

940
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
940
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

153
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
153
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

282
The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
282
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

1.8K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.8K
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

134
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
134
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

548
Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
548

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Clinical outcomes of intravascular imaging-guided versus angiography-guided drug-coated balloon angioplasty for de novo coronary lesions.

International journal of cardiology·2026
Same author

Drug-coated balloon versus drug-eluting stent for isolated ostial side-branch bifurcation (Medina 0.0.1) lesions.

International journal of cardiology·2026
Same author

Sex Differences in Prognostic Implications of CYP2C19 Genotype After Drug-Eluting Stent Implantation.

Journal of the American Heart Association·2026
Same author

Effectiveness and Safety of Biodegradable Polymer-Coated Everolimus-Eluting Stent in Multivessel Coronary Artery Disease in Routine Clinical Practice: A Korean Multicenter, Prospective, and Observational Study.

Journal of Korean medical science·2026
Same author

Drug-Coated Balloon-Based Versus Drug-Eluting Stent-Only Treatment in Patients With Chronic Kidney Disease.

The American journal of cardiology·2026
Same author

Drug-Coated Balloon-Based Versus Drug-Eluting Stent-Only Treatment for Patients With High-Bleeding Risk.

Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions·2026

関連する実験動画

Updated: Dec 18, 2025

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

1.4K

急性冠動脈症候群の患者における重大出血および心血管疾患に対するチカグレロ単独療法とアスピリンの効果: TICOランダム化臨床試験

Byeong-Keuk Kim1, Sung-Jin Hong1, Yun-Hyeong Cho2

  • 1Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, South Korea.

JAMA
|June 17, 2020
PubMed
まとめ

急性冠動脈症候群の患者で,二重抗血小板療法 (DAPT) の3ヶ月後にチカグレロール単独療法に切り替えると,不良臨床事象が有意に減少した. この戦略は12ヶ月のDAPTと比較して大きな出血を減少させました.

さらに関連する動画

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

5.7K
Upper-extremity Approach for Secondary Access in Transfemoral Transcatheter Aortic Valve Implantation
06:04

Upper-extremity Approach for Secondary Access in Transfemoral Transcatheter Aortic Valve Implantation

Published on: August 8, 2025

437

関連する実験動画

Last Updated: Dec 18, 2025

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

1.4K
Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

5.7K
Upper-extremity Approach for Secondary Access in Transfemoral Transcatheter Aortic Valve Implantation
06:04

Upper-extremity Approach for Secondary Access in Transfemoral Transcatheter Aortic Valve Implantation

Published on: August 8, 2025

437

科学分野:

  • 心臓病科
  • 臨床試験
  • 薬理学について

背景:

  • 二重抗血小板治療 (DAPT) は,急性冠動脈症候群 (ACS) の薬剤排出ステント (DES) 置換後の標準治療である.
  • DAPTからのアスピリンの中止は出血の減少戦略ですが,チカグレロの単独治療の役割はACSにおいて特定の評価を必要とします.

研究 の 目的:

  • 3ヶ月のDAPTと12ヶ月のDAPTを比較して,DES患者におけるACSにおける不良事象を比較する.
  • チカグレロル単独治療の後のDAPTの安全性と有効性を評価する.

主な方法:

  • DESで治療された3056人のACS患者を対象としたランダム化マルチセンター試験.
  • 患者は3ヶ月のDAPTとチカグレロ単独治療,または12ヶ月のチカグレロベースのDAPTを受けた.
  • 主なアウトカムは,1年間の重度の出血と重度の心血管不良事件の複合でした.

主要な成果:

  • 3ヶ月のDAPTの後にチカグレロール単独治療は,不良事象の統計的に有意な減少を示した (3. 9% 対 5. 9%).
  • 重度の出血はチカグレロ単独治療群では有意に減少した (1. 7% 対 3. 0%).
  • 主要な心動脈および脳血管に関する有害事象は,グループ間では有意な差異は見られなかった.

結論:

  • 3ヶ月のDAPT後のチカグレロ単独治療は,DESのACS患者にとって実行可能な戦略であり,不良臨床イベントの純量をわずかに減らすことができます.
  • このアプローチは,重大な心臓および脳血管の有害事象を増加させることなく,大きな出血を減少させるように見える.
  • 裁判令状の解釈の際に予想より低い事件発生率